Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 87979

Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients.


Pavićević, Radomir; Bubanović, Gordana; Krajina, Ana; Miličić, Jasna; Bialik, Petra; Pavićević, Lukrecija
Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients. // European Respiratory Journal, Vol. 18, (Suppl.) 33, / European Respiratory Society (ur.).
Berlin, 2001. (poster, međunarodna recenzija, sažetak, znanstveni)


CROSBI ID: 87979 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients.

Autori
Pavićević, Radomir ; Bubanović, Gordana ; Krajina, Ana ; Miličić, Jasna ; Bialik, Petra ; Pavićević, Lukrecija

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
European Respiratory Journal, Vol. 18, (Suppl.) 33, / European Respiratory Society - Berlin, 2001

Skup
11th ERS Annual Congress

Mjesto i datum
Berlin, Njemačka, 22.09.2001. - 26.09.2001

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
CYFRA 21-1 tumor marker; longitudinal follow up; responce to therapy; NSCLC
(CYFRA-21-1 tumor marker; longitudinal follow up; responce to therapy; NSCLC)

Sažetak
In this study we presented dynamics of tumor marker CYFRA 21-1 level that is evaluated as a response to therapy (surgery or chemotherapy) in 500 NSCLC patients. Serum level of CYFRA 21-1 was measured with electrochemiluminescence method using fully automated system Elecsys 2010 (Roche Diagnostics). The level of CYFRA 21-1 in NSCLC patients was determined before and after the therapy. In 95% surgically treated patients we observed a significant decrease of CYFRA 21-1 level after the therapy to the average level of healthy population (p<0.001). In 5% patients the increase of CYFRA 21-1 level was observed after the surgery, which indicated the tumor biological activity. This allowed the clinicians to apply an additional therapy. From 141 patients who underwent surgery followed by chemotherapy in 35% CYFRA 21-1 level indicated the inefficiency of therapy, which was also proved clinically. This allowed the clinicians to replace applied chemotherapy.Introducing the protocol including the evaluation of CYFRA 21-1 level before and after therapy we proved the contribution of tumor marker CYFRA 21-1 to the selection and control of therapy and the assessment of therapy efficiency.

Izvorni jezik
Engleski

Znanstvena područja
Etnologija i antropologija



POVEZANOST RADA


Projekti:
01960101

Ustanove:
Institut za antropologiju


Citiraj ovu publikaciju:

Pavićević, Radomir; Bubanović, Gordana; Krajina, Ana; Miličić, Jasna; Bialik, Petra; Pavićević, Lukrecija
Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients. // European Respiratory Journal, Vol. 18, (Suppl.) 33, / European Respiratory Society (ur.).
Berlin, 2001. (poster, međunarodna recenzija, sažetak, znanstveni)
Pavićević, R., Bubanović, G., Krajina, A., Miličić, J., Bialik, P. & Pavićević, L. (2001) Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients.. U: European Respiratory Society (ur.)European Respiratory Journal, Vol. 18, (Suppl.) 33,.
@article{article, author = {Pavi\'{c}evi\'{c}, Radomir and Bubanovi\'{c}, Gordana and Krajina, Ana and Mili\v{c}i\'{c}, Jasna and Bialik, Petra and Pavi\'{c}evi\'{c}, Lukrecija}, year = {2001}, pages = {377s}, keywords = {CYFRA 21-1 tumor marker, longitudinal follow up, responce to therapy, NSCLC}, title = {Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients.}, keyword = {CYFRA 21-1 tumor marker, longitudinal follow up, responce to therapy, NSCLC}, publisherplace = {Berlin, Njema\v{c}ka} }
@article{article, author = {Pavi\'{c}evi\'{c}, Radomir and Bubanovi\'{c}, Gordana and Krajina, Ana and Mili\v{c}i\'{c}, Jasna and Bialik, Petra and Pavi\'{c}evi\'{c}, Lukrecija}, year = {2001}, pages = {377s}, keywords = {CYFRA-21-1 tumor marker, longitudinal follow up, responce to therapy, NSCLC}, title = {Clinical contribution of tumor marker CYFRA 21-1 in evaluation of response to therapy in NSCLC patients.}, keyword = {CYFRA-21-1 tumor marker, longitudinal follow up, responce to therapy, NSCLC}, publisherplace = {Berlin, Njema\v{c}ka} }




Contrast
Increase Font
Decrease Font
Dyslexic Font